• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245227 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& d, a+ D" R3 _! c! j9 t* r
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 + r. k: L6 g1 N7 t
+ Author Affiliations
, M/ h7 v4 W: P, u% G
4 O/ e  A' L; M+ o# \& A' U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 [. s6 i8 R/ Z# U; m3 Y
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 q# I8 x3 D  K/ @# ^
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & H, ^) F: H/ n
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
1 G9 }  v5 ^9 k9 |4 g$ \5 |' c5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
0 ~2 Y$ ^" }* u$ E2 r6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 d2 B) n& q+ v' m. ]5 W6 `7Kinki University School of Medicine, Osaka 589-8511, Japan
2 i0 D; J) ?' c2 s8Izumi Municipal Hospital, Osaka 594-0071, Japan , V7 q' N3 P! Z5 Z. O/ n0 s, A* u
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan " r) I: U1 F; U- G9 Y- E0 Y
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp & i1 `  N- N- `- a3 q
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. + |5 O( G# y; V* N2 M9 `- T

5 K( w5 E. B# f& b, Y( D( V* m
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 7 X% W5 [5 U7 R6 l0 J( k9 P
8 y# D9 y! e0 S" Z/ a6 U3 F' Z: c* G
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
: Z& |/ ^7 ^/ y3 l9 l: r
. a8 v3 y: q! ?Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
. A" }, J' ~9 t
' q& s2 P: z. x6 @3 C* xPublished online on: Thursday, December 1, 2011
/ C# f( h* K# _  H' P4 H; t( O& {$ P8 {& `( y
Doi: 10.3892/ol.2011.507 % ?3 i& J4 E+ e' Z$ R

3 C# [0 m. X' a( [Pages: 405-410 1 C, ?# F, S+ l9 i4 ^- k

2 x$ s& }8 K. nAbstract:
' o8 O- D# {1 s. Z" s9 zS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.- f0 a4 P) w2 s( x" E$ M7 _, f' T7 P

$ z5 }& _" F- q3 u  g, `3 ]
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. h4 r7 q- U, J, M5 y$ d
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
1 I8 J$ U  E) u* v/ o  P+ Author Affiliations
! D9 L) |% G: e1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
) F3 C; q3 I# [8 l9 R7 M2Department of Thoracic Surgery, Kyoto University, Kyoto , u+ Y. X. y6 c
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan - O  q; `0 C% c# t" P5 W
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp / e; ~3 z% P+ u$ }* Y
Received September 3, 2010.
, ]$ }" ]3 g1 ^) ^Revision received November 11, 2010. ; u/ m6 d  h; m
Accepted November 17, 2010.
' \7 e- F! Z( [Abstract1 @  O- Z2 Z, U+ G# v% `
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
( f6 S4 X$ e3 @8 T* Q7 X1 d2 TPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 6 e8 ?5 a! r5 L! K' X! Q1 ^9 c* ^
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
! `6 Y/ m0 I5 j  N! r) o& e' K  GConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. & L) O/ ~5 j; d" w* t- V
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
2 q$ k+ z5 a+ v今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?0 t. K# G, A7 U# j2 d
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
6 L0 Y$ u8 o+ O: l* w3 ihttp://clinicaltrials.gov/ct2/show/NCT01523587
- y+ f6 O7 p  Q- N2 m" V! a
& A8 q% P  s4 n2 }, bBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
' ?' }# c' |: Z5 ghttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 0 i$ i3 L' G0 \  O0 _. p
  v( I" P$ c8 o5 m- P+ {; Z
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
7 Q1 f- t  e: v- c至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
; Y, L; y# A; T9 h; `0 w* x从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
7 Q: T. E0 G4 Q) c5 S3 h) m0 T至今为止,未出 ...
, g) \4 D& ?0 o4 Q7 |
没有副作用是第一追求,效果显著是第二追求。  X- }0 @, N& c
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表